Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dianicline · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| dianicline | DRUG | - |
Inclusion Criteria: * Outpatients over the legal age smoking at least 10 cigarettes per day for at least 2 months Exclusion Criteria: * Insufficient level of motivation * Another participant in the household * Patients with current psychotic disorder or major depressive disorder The investigator...
Dianicline is an investigational small molecule being developed as an aid to smoking cessation. It is intended to help people stop smoking, and it has been studied in a Phase 3 clinical trial for this purpose. The drug is not approved and remains in clinical development.
Dianicline is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi has conducted clinical research on dianicline for smoking cessation, including a Phase 3 trial that has been completed.
Dianicline is in Phase 3 of clinical development. A Phase 3 trial, NCT00356967, has been completed. This trial was a randomized, double-blind study designed to evaluate the efficacy and safety of dianicline versus placebo as an aid to smoking cessation. The drug is still investigational and not approved.
Dianicline has been studied in one clinical trial, NCT00356967, which is a Phase 3 study titled 'Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation.' This trial enrolled 602 participants and was conducted in Belgium, Denmark, France, Norway, Spain, and Sweden. The trial has been completed.
Dianicline is not FDA approved. It is an investigational drug that has been studied in clinical trials for smoking cessation, including a completed Phase 3 trial. However, approval status has not been established, and the drug remains in clinical development.